1736. Deputy Erin McGreehan asked the Minister for Health the measures being considered at EU level, during Ireland’s Presidency, to ensure that SMEs and indigenous biotech companies involved in cell therapies, gene therapies and orphan drug development are not disproportionately impacted by increased regulatory obligations under the EU pharma package; and if she will make a statement on the matter. [42965/26]

Summary

1736. Deputy Erin McGreehan asked the Minister for Health the measures being considered at EU level, during Ireland’s Presidency, to ensure that SMEs and indigenous biotech companies involved in cell therapies, gene therapies and orphan drug development are not disproportionately impacted by increased regulatory obligations under the EU pharma package; and if she will make a statement on the matter. [42965/26]

This text is taken from the official record. PoliticalRepo does not editorialize.

Timeline

No timeline events have been ingested for this record yet.

Votes

No vote records are attached yet.

Versions

No version snapshots stored. Document URLs remain at the source.

Documents

1 official file

• EU Presidency

  xml · EN · 9 June 2026

  ViewDownloadOpen at official source

Sponsors

No sponsors or actors listed by the source.

Related records

No cross-record relationships stored yet.